MTOR and ovarian cancer: We found that TAK-165/AC220 combination was much more effective than treatment with either compound alone in reducing the phosphorylation of Akt Ser473 site and mTOR Ser2448 site, the biomarkers of their activation, as well as that of S6, which is downstream of mTORC1 signaling, in ES-2 (ovarian cancer), Sum159 (breast cancer) and Sum149 (triple negative breast cancer) cell lines (Fig. 4b).